The public is keeping a close eye on the South Korean Ministry of Food and Drug Safety (MFDS) approving the COVID-19 vaccine and treatment. Especially because the pharmaceuticals and their efficacy have been controversial overseas, the public’s interest is heightened on the result of the health authority’s evaluation.

To guarantee an objective assessment, MFDS is consulting with experts for three times. After the first verification, the Central Pharmaceutical Affairs Deliberation Committee and the Final Review Committee would conduct the second and third review on the drugs, respectively, for the final decisions

Celltrion’s COVID-19 monoclonal antibody treatment candidate Rekirona h